Best Startup
At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United Kingdom based President operating in the Health Care space. If you think a President is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Arjun Purkayastha
Senior Vice President – eCommerce, Digital & Ventures of Reckitt
Arjun Purkayastha is a purpose driven leader with extensive global experience managing diverse businesses and multi-cultural teams at FTSE Top 10 and Fortune 100 companies – RB and P&G. He has a strong track record of building outperforming teams, iconic brands & innovative business models across 60+ countries having lived & worked in the UK, Singapore, South Korea and India. He currently leads eCommerce, CRM, digital, DNVB & start up ventures globally for RB with P&L, strategic and operational responsibility of all online channels & customers. He serves on the Board of Directors of 4 high growth, online focused companies – Pharmapacks.com (one of the largest and best 3P resellers on Amazon), Bombay Shaving Company (leading men’s wellness company in India), UpSpring (mom & baby products) and Healthily by Your.MD (AI powered self care). He is also an Investment Committee Member of Founders Factory & RB’s JV focused on Hygiene & Home start ups.
Follow Arjun Purkayastha:
About Reckitt: Reckitt Benckiser Group is a consumer goods company makes health, hygiene and home products.
Shaun Grady
Vice-President Business Development Operations of AstraZeneca
Shaun Grady has responsibility for Global Business Development at AstraZeneca, leading the company’s transaction execution, due diligence and Alliance and Integration Management function including externalisation, licensing and partnering, M&A, and divestments. Shaun was appointed to his current role in 2013 with the creation of the Global Product and Portfolio Strategy (GPPS) unit. Prior to this, he was Vice President, Strategic Partnering & Business Development (2010-13) and Vice President, Corporate Business Development (2006-10). Shaun originally joined ICI as an attorney and held positions in the pharmaceuticals, petrochemicals, and legal departments. Following the demerger from ICI, he was appointed Assistant General Counsel, Corporate for Zeneca. Shaun worked on the merger of Astra and Zeneca, the merger of Zeneca Agrochemicals with Novartis Agribusiness to form Syngenta, and the creation of Avecia. Shaun also worked on the acquisition of Cambridge Antibody Technology (CAT), led the acquisition of Amylin, and subsequent buy-out of Bristol-Myers’ Squibb’s interest in the AZ-BMS Diabetes Alliance. In addition, he has spent time in the US business managing the legal function and also completed a two year secondment to HR, leading a global People Strategy change project. Shaun is an Honorary Fellow in Entrepreneurship at Cambridge Judge Business School and is a member of the Board of Cambridge United Football Club and Cambridge Arts Theatre. Based in Cambridge, Shaun enjoys rugby and football, and occasionally turns his hand to sports writing.
Follow Shaun Grady:
About AstraZeneca: AstraZeneca is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines.
Emmanuel Ligner
President & CEO, Life Sciences of GE Healthcare
Emmanuel joined GE Healthcare in April 2008, following its acquisition of Whatman International Plc. Since 2008, Emmanuel has held various positions in GE Healthcare Life Sciences. Working both in the UK and in the US, he managed the North America BioProcess business. In January 2012, Emmanuel took charge of the Commercial part of the then Life Sciences business, across EMEA, later expanding his role to include global commercial leadership of BioProcess. In January 2016, Emmanuel was name General Manager of the Core Imaging business which he held until he was named President and CEO of Life Sciences In July 2017. Emmanuel first entered the biopharma industry in Japan, joining Ostuka Pharmaceutical International Ltd as a Medical Representative in Tokyo. After five years in Ostuka in various roles, Emmanuel joined Abbott Japan, occupying positions such as Marketing Director Diagnostic Division and Commercial Director Diabetes Care Division. After 10 years in Japan, Emmanuel moved to the UK as Vice President Sales & Marketing Europe for Whatman International Plc.
Follow Emmanuel Ligner:
About Cytiva, GE Healthcare: GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care.
Jan Makela
President and CEO, Imaging at GE Healthcare of GE Healthcare
Jan Makela is the President & CEO of GE Healthcare Global Services. Appointed in December 2017, he oversees the global development and execution of GE Healthcare’s service solutions and operations around the globe.
Follow Jan Makela:
About GE Healthcare: GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care.
Kieran Murphy
President & CEO of GE Healthcare
Kieran Murphy is President and CEO of GE Healthcare, a $20 billion business unit of General Electric that provides transformational medical technologies and solutions to the global healthcare industry. GE Healthcare supports customers in over 100 countries with a broad range of services and systems, from diagnostic imaging and healthcare IT through to molecular diagnostics and life-sciences. Prior to this, Kieran was President and Chief Executive Officer of GE Healthcare Life Sciences, a $3.7 billion molecular medicine business that provides a broad range of industry-leading technologies and services for drug discovery, pre-clinical and clinical development and biopharmaceutical manufacturing, as well as molecular tools for diagnostics, therapy selection and treatment monitoring in patient care. Kieran was appointed CEO in May 2011 and oversaw significant revenue growth and geographic expansion of the molecular medicine business. Kieran joined GE Healthcare in 2008 from Whatman plc, a $230 million global supplier of filters and membranes for laboratory research, life sciences and medical diagnostic applications. Kieran has over twenty years’ experience in the global life sciences and biotechnology industry, beginning his career with Janssen Pharmaceutical, a division of Johnson and Johnson, followed by leadership roles with Mallinckrodt, veterinary medicines provider Vericore, Novartis, Adprotech, ML Laboratories and Innovata plc.
Follow Kieran Murphy:
About GE Healthcare: GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care.
Mark Cooper
Vice President and Managing Director, Avery Europe and Asia Pacific of CCL Industries
Mark Cooper is a Vice President and Managing Director, Avery Europe and Asia Pacific at CCL Industries.
Follow Mark Cooper:
About Avery, CCL Industries: CCL is the largest label company in the world and provides innovative solutions.
Jamie Robinson
Vice President and Managing Director, Home & Personal Care Europe of CCL Industries
Jamie Robinson is a Vice President and Managing Director, Home & Personal Care Europe at CCL Industries.
Follow Jamie Robinson:
About CCL Industries: CCL is the largest label company in the world and provides innovative solutions.
Steve Cahillane
President & Chief Executive Officer of NBTY
Steve Cahillane joined NBTY in September 2014 as President & CEO. Since that time, he has also served as a member of the Board of Directors of NBTY. Prior to joining NBTY, Steve served as President of Coca-Cola Americas, which consists of both the North American and Latin American operations. Before assuming that role, he held positions as President and CEO of Coca-Cola Refreshments (CCR), an operating unit of the North American business of The Coca Cola Company, and President of Coca-Cola Enterprise’s (CCE) North American business. Mr. Steven A. Cahillane, also known as Steve, has been the Chief Executive Officer and President at Kellogg Company since October 2, 2017 and has been its Chairman since March 16, 2018. Mr. Cahillane possesses particular knowledge and experience in a variety of areas, including accounting and financial acumen, risk management, innovation and research and development, branded consumer products and consumer dynamics, regulatory and government that strengthens the Board’s
Follow Steve Cahillane:
About Kellogg’s, NBTY: NBTY is a leading global vertically integrated manufacturer, marketer and distributor.
Mark Wenham
Executive Vice President of Multi Packaging Solutions
Mark Wenham was appointed to the position of Executive Vice-President at Multi Packaging Solutions in November 2014. Mark has responsibility for all European operations dedicated to the Healthcare market. Previously Mark served as managing director for Chesapeake’s UK, Ireland and Asia healthcare operations and has been with the company for 18 years. He has thorough understanding of the business through a variety of roles including responsibility for its Benelux sites and a management period in the U.S. A lithographic printer by training, Mark has worked for over 33 years in the print and packaging sector. During his tenure, Mark has directed the business through a period of strong growth and he has overseen an unprecedented investment program resulting in new equipment at every location.
Follow Mark Wenham:
About Multi Packaging Solutions: Multi Packaging Solutions provides packaging solutions for healthcare markets.
Jeanne Bolger
Vice President Venture Investing of Johnson & Johnson Development Corporation
Jeanne Bolger, MB BCh BAO, Vice President, Venture Investments, joined Johnson & Johnson Development Corporation (JJDC) in 2013. She is based in London, UK. Dr. Bolger has over 25 years of pharmaceutical industry experience in management roles across R&D, Commercial and Business Development (BD). She spent 11 years in Licensing and Acquisition (L&A), most recently as Global Head of Scientific Licensing for Johnson & Johnson’s Pharmaceutical business, having joined Johnson & Johnson in 2005 from the Business Development group at GlaxoSmithKline. In 2009, Dr. Bolger became Vice President, Alliance Management at Janssen Alzheimer Immunotherapy, working with Pfizer and Elan. Dr. Bolger received her medical degree from University College Dublin. She also holds diplomas in Child Health (NUI) and in Finance and Accounting (ACCA). She is a Fellow of the Royal Academy of Medicine of Ireland (RAMI). Dr. Bolger has served as the sole pharma industry representative on two Irish government taskforces seeking to enhance the commercialization of IP from Irish academic centres. She is a visiting lecturer on the MSc Pharmaceutical Medicine curriculum at Trinity College in Dublin, Ireland.
Follow Jeanne Bolger:
About Johnson & Johnson Development Corporation, Pulmocide: Johnson & Johnson Development Corporation, a venture capital subsidiary, finances technology companies focused on patient health.
Victoria Kitcatt
Vice President and Assistant General Counsel of Pfizer
Follow Victoria Kitcatt:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
Dipankar Bhattacharjee
President & CEO: Generics Europe of Teva Pharmaceutical Industries
Mr. Dipankar Bhattacharjee was appointed President and CEO, Generics Europe in April 2013. Mr. Bhattacharjee joined Teva as Chief Executive Officer, Teva UK Limited in 2009. Prior to joining Teva, he served 15 years at Bausch + Lomb in various senior roles, including Vice President, Commercial in both Europe and Asia-Pacific regions, and Corporate Vice President and President, Asia Pacific Region. Mr. Bhattacharjee began his career at Nestlé SA and Bank of America. Mr. Bhattacharjee received a BA in Economics from St. Stephens College, University of Delhi, and a Masters degree in Management Studies from Jamnalal Bajaj Institute of Management Studies, University of Mumbai.
Follow Dipankar Bhattacharjee:
About Teva Pharmaceutical Industries: Teva Pharmaceutical Industries is a pharmaceutical company specializing in the development, production and marketing of generic.
Michael Gibbs
Co-founder & President of Second Nature
Cambridge pharmacology graduate, strategy consultant, entrepreneur, author, health and nutrition geek. Incredibly strong believer in immersing yourself in the details of science and physiology – rather than the face value of published scientific papers – in order to come to a critical viewpoint on nutrition and public health. “It is simply no longer possible to believe much of the clinical research that is published, or to rely on the judgement of trusted physicians or authoritative medical guidelines” – Marcia Angell, long-time editor of the New England Journal of Medicine.
Follow Michael Gibbs:
About Second Nature: Second Nature is a digital programme that helps people lead healthier lives
Anne Prener
President & CEO of Imbria Pharmaceuticals
Anne brings to Freeline over 25 years of experience in drug development and executive leadership across several therapeutic areas, with special focus on rare diseases and gene therapy. Anne most recently served as the CEO of Gyroscope Therapeutics, a preclinical gene therapy company focusing on ophthalmology, where she continues to serve as a non-executive Member of the Board. From 2014-2016, Anne was VP of Clinical Research Haematology and Global Therapeutic Area Head of Haematology in Baxalta, Boston, USA. In this role, she secured several new product approvals (US and EU). Before this, Anne held a number of senior leadership positions in a broad range of functional areas at Novo Nordisk, Denmark, leading global drug development programmes from research to commercialisation, and bringing several products to market globally. Anne has an MD from Copenhagen University and holds a PhD in Epidemiology.
Follow Anne Prener:
About Imbria Pharmaceuticals, Kaleido BioSciences: Imbria Pharmaceuticals is a biotechnology company with locations in San Diego, CA, and Boston, MA.
John Wigneswaran
Vice President of Clinical Affairs of DaVita
Follow John Wigneswaran:
About DaVita: DaVita is a provider focused on transforming care delivery to improve quality of life for patients globally.
Mustapha Rashid
President of British Orthopaedic Trainees Association
Follow Mustapha Rashid:
About British Orthopaedic Trainees Association: Supporting the orthopaedic trainees of today, for the patients of tomorrow
Disa Sanstorn
Senior Vice President Business Development Europe of YgEia3
Follow Disa Sanstorn:
About YgEia3: YgEia3 works with corporations developing comprehensive wellness testing for each company.
Vincent Miceli
Vice President & Chief Financial Officer of NXT-ID
Vincent Miceli, age 56, has extensive hands on experience in financial and operational management and business leadership in both substantial private and public companies. He is also experienced with working with public company Boards of Directors, as well as financial institutions. Vincent Miceli was the Vice-President and Chief Financial Officer/Treasurer of Panolam Industries International, Inc., a company which primarily designs, manufactures and distributes decorative and industrial laminates, from May 2006 to mid-December 2013. Prior to that, Vincent Miceli was the Chief Financial Officer and Corporate Controller of Opticare Health Systems, Inc., a public company which provides integrated eye care services, from 2004 to 2006. Prior to 2004, Vincent Miceli held senior accounting positions at Amphenol Corporation and United Technologies, Inc. Vincent Miceli holds a BS in accounting from Quinnipiac College, an MBA, with a concentration in Finance, from the University of Hartfordand he is an affiliate member of both the AICPA and the CT Society of Certified Public Accountants.
Follow Vincent Miceli:
About NXT-ID: Sensor, Mobile, HealthTech, MedTech
Pablo Graiver
President and Founder of Antidote.me
Pablo Graiver is Co-Founder of Antidote Technologies Ltd. (a/k/a TrialReach Ltd.) and serves as its Chief Executive Officer and Executive Director. Pablo Graiver served as Vice President of Business Development, Europe of Kayak Software Corporation. He has over 12 years of entrepreneurial and management experience in the online industry. He was an early member of NetJuice, one of the largest Internet incubators in Europe; MD at Donde Comprar.com, the first e-commerce directory in Spanish; and later co-founder and Vice President of Strategy at Kelkoo, acquired by Yahoo! in 2004. Pablo Graiver set up and launched Kayak.com in Europe, and served as European Sales Director at ValueClick (NASDAQ: VCLK). He studied Biology and Business Administration at UAM in Madrid.
Follow Pablo Graiver:
About Antidote.me: Antidote is a digital health company that accelerates and improves medical research by combining technologies, data, and business models.
Paul Lyons
Vice President of Platform Delivery & Co-Founder of PredictImmune
Paul is a Principal Research Associate in the Department of Medicine at the University of Cambridge. He has over 25 years of experience in molecular and cellular biology including Senior Scientist positions in the Dept. Medical Genetics, University of Cambridge, Dept. Surgery, University of Oxford and the Rosalind Franklin Centre for Genomics Research. His primary research interest is the application of high throughput genomic approaches to better understand the genetic and molecular basis of autoimmune disease.
Follow Paul Lyons:
About PredictImmune: Providing tools to physicians in the treatment of patients with immune-mediated disease, through prediction of long term clinical prognosis.
Colin Hutchison
Vice President of International of Edgewell Personal Care
Colin joined Energizer in 2004 as Vice President Europe for Wilkinson Sword. In 2006 he led the successful integration of the Personal Care and Household Divisions in Europe. After the Playtex acquisition, he became Vice President for Personal Care in Europe and led planning for the distribution expansion of Hawaiian Tropic and the Hydro brand launch. After the American Safety Razor acquisition, Colin was appointed Vice President and General Manager for EPC’s Private Brands Group. Overseeing strategic development for the global private label wet shave business, he reshaped the portfolio and developed a roadmap for growth through NPD and distribution expansion. Additionally, he led the integration of most functions into the wider Personal Care business structures. Prior to Edgewell, Colin worked for a number of consumer goods businesses based in Europe including United Biscuits and the Campbell’s Soup Company. He held various positions in sales, marketing, and general management that latterly included international responsibilities.
Follow Colin Hutchison:
About Edgewell Personal Care, Energizer Holdings: Edgewell Personal Care manufactures and markets a diversified range of personal care products.
Paul Grabscheid
Vice President of Strategic Planning of Intersystems
Since 1986, Paul Grabscheid has used his expertise in database and application development tools and technologies in a variety of product planning and marketing roles at InterSystems. Prior to that, he served as director of marketing for Mathematica, a database and 4GL software company, helping to expand the company’s worldwide presence. When the company was acquired by Martin Marietta he served as director of marketing for that firm’s Information Technology Division, overseeing marketing efforts for a number of system software, application software, and computer services product lines. Grabscheid’s background also includes consulting work involving the development of decision support systems for state governments. He holds a master’s degree from the Sloan School of Management at the Massachusetts Institute of Technology.
Follow Paul Grabscheid:
About Intersystems: InterSystems is a vendor of software and technology for high-performance database management, integration, and health information systems.
Olivier de Beauminy
President of Medylink
Follow Olivier de Beauminy:
About Medylink: Medylink has designs and develops a digital platform that allows general practitioners to coordinate their actions with specialists.
Simon Viggers
Vice President Human Resources of Otsuka Pharmaceuticals
Simon Thule Viggers is a Senior HR Leader with deep global experience. Almost 20 years of experience within Pharma, 15 years in leadership roles across three continents. Proven ability to lead through challenging change and with an ability to approach business in a holistic way. Simon takes the starting point in the business agenda and translates that into actions for the organization and the people. Simon has a strong leadership background as he has been part of executive teams for more than a decade and has been preferred coach to many executives.
Follow Simon Viggers:
About Otsuka Pharmaceuticals: Otsuka Pharmaceuticals is a pharmaceutical company that operates throughout the globe.
Gareth Ridge
Senior Vice President of Operations & Site Head of Cambridge Epigenetix
Gareth has a degree in Pharmacology from the University of Cambridge and has worked in the pharmaceutical sector for over 20 years. During his career he has worked for both large and small pharma, biotechnology and clinical research organisations, he also has five years’ experience in business consultancy. In addition to delivering successful clinical research projects Gareth has managed business change projects – including system implementations, process reengineering and organisational change. He has held many leadership positions with responsibility for project and revenue delivery and strategic growth and has had oversight of over 70 clinical research studies, either directly as project manager or as responsible head, and has worked in high growth companies where he successfully built a team to successfully deliver 700% growth in project delivery & revenue in 2 years.
Follow Gareth Ridge:
About Cambridge Epigenetix: Cambridge Epigenetix is using epigenetics to reduce several routine & important diagnostic tests for common cancers to a simple blood draw.
Joanna Holbrook
Senior Vice President of Research of Cambridge Epigenetix
Joanna started her career in GSK R&D, working for seven years in the UK bioinformatics department, processing the integrating ‘omic data for drug target identification and validation mostly focussing on neurological disease, and then for three years in GSK USA Oncology R&D working on biomarkers for targeted therapies. She then left GSK and the USA for Singapore and built an academic group in A*STAR Singapore Institute for Clinical Sciences. Her group focused on epigenomic trackers of complex disease, especially the interaction of genetic, environmental and disease states in shaping the human epigenome. Her work in Singapore encompassed set-up of observational and interventional cohorts, biobanking, clinical databases, production, processing and analysis of biosample ‘omic profiles and multiple industrial collaborations. Moving back to the UK five years later, she took up a professorship at the University of Southampton, still working on epigenomics and also integration of electronic health record data to clinical cohorts. Most recently she has been VP of Translational Medicine at BenevolentAI, a fast growing British Biotech, where she initiated and led integration of ‘omic data into a large biomedical knowledge graph and machine learning approaches to analyses of patient-level data for precision medicine.
Follow Joanna Holbrook:
About Cambridge Epigenetix: Cambridge Epigenetix is using epigenetics to reduce several routine & important diagnostic tests for common cancers to a simple blood draw.
William Haseltine
Chairman and President of ACCESS Health International
William A. Haseltine, PhD, has an active career in both science and business. He was a professor at Harvard Medical School and Harvard School of Public Health from 1976 to 1993, where he was founder and the chair of two academic research departments, the Division of Biochemical Pharmacology and the Division of Human Retrovirology.He is well known for his pioneering work on cancer, HIV/AIDS, and genomics. He has authored more than two hundred manuscripts in peer reviewed journals and is the author of several books, including Affordable Excellence: The Singapore Healthcare Story, published in 2013. He is the founder of Human Genome Sciences, Inc., and served as the chairman and CEO of the company until 2004. He is also the founder of several other successful biotechnology companies. Companies he has founded account for seven drugs currently on the market. He is chairman of the Haseltine Foundation for Science and the Arts. He serves as an advisor and board member of several innovative healthcare companies.
Follow William Haseltine:
About ACCESS Health International, Demetrix: ACCESS Health International is a nonprofit think tank and advisory group dedicated to improving access to high quality.
Laurence Tisi
President of ERBA Diagnostics Mannheim
Follow Laurence Tisi:
About ERBA Diagnostics Mannheim, Lumora: ERBA Diagnostics Mannheim is a global in vitro diagnostics company.
Patrick Darby
Executive Vice President, General Counsel & Corporate Secretary of Encompass Health Corp.
Patrick Darby was named executive vice president, general counsel and corporate secretary of HealthSouth in February 2016. Prior to joining us, Darby was a partner of the law firm of Bradley Arant Boult Cummings LLP, in Birmingham, Alabama. He is listed in Chambers USA, The Best Lawyers in America and Alabama Super Lawyers. He received his bachelor’s degree from Dartmouth College and his law degree from Washington & Lee University School of Law, where he was editor-in-chief of the Washington & Lee Law Review.
Follow Patrick Darby:
About Encompass Health Corp.: Encompass Health Corp. (HealthSouth), is an owner and operator of inpatient rehabilitation hospitals.
Philip M. Toleikis
President & CEO of Sernova
Dr. Toleikis is President and Chief Executive Officer of Sernova Corp since April 2009. From 2006 until 2009, Dr. Toleikis consulted for multiple device, combination product and pharmaceutical companies. From 1996 to 2006 he held multiple roles at Angiotech Pharmaceuticals, Inc. including Vice President, Research and Development – Pharmacology and Drug Screening where he built a product development team of over 50 scientists and was responsible for multiple corporate and academic product development collaborations. While at Sernova, Dr. Toleikis has secured over $60 million in various forms of financings, including equity raises and multiple non-dilutive grants and has been responsible for negotiating a worldwide exclusive license with UHN and University of Miami for its stem cell derived technologies as well as developing business relationships and or collaborations with multiple pharmaceutical and academic institutions involving its Cell Pouch™ device and cell technologies. Dr. Toleikis is an author of over 100 patent applications ande issued patents, and multiple scientific publications involving transplantation, metabolic, cardiovascular, oncology, and autoimmune disease. He obtained his Ph.D. in Medicine, Pharmacology and Therapeutics from the University of British Columbia, his M.Sc. at the University of Michigan and B.A. at the University of Vermont.
Follow Philip M. Toleikis:
About Sernova: Sernova develops regenerative medicine therapeutic technologies for treatment of chronic metabolic diseases.
Lindsay Edwards
Chief Technology Officer and President of Platform of Relation Therapeutics
Lindsay Edwards is the Chief Technology Officer and President of Platform of Relation Therapeutics.
Follow Lindsay Edwards:
About GlaxoSmithKline, Relation Therapeutics: Relation Therapeutics engages in humanizing drug discovery and development.
Clare Cooper
Founder and Vice President of Storm3
Clare Cooper is the Founder and Vice President at Storm3.
Follow Clare Cooper:
About Storm3: Storm3 are a global HealthTech talent marketplace, connecting organizations with the talent to drive their mission.
William Richardson
Executive Vice President of Savaria Corp
Follow William Richardson:
About Savaria Corp: Savaria provides accessibility solutions for the elderly and physically challenged to increase their mobility and independence.
Richard Lagani
Executive Vice President of MMRGlobal
Richard Lagani is an Senior Management Professional
Follow Richard Lagani:
About MMRGlobal, MMRGlobal: MMRGlobal provides secure, easy-to-use multilingual personal health records (PHRs) and electronic safe deposit box storage solutions.
Nick Child
Vice President of Stablepharma Ltd
Nick Child – Vice President & Co Founder Experienced company leader, business developer, multi-disciplined & experienced in UK & International markets, manufacturing & distribution. Initiated various start-ups, acquisitions, & funding rounds.
Follow Nick Child:
About Stablepharma Ltd: An innovative Biotech, developing a wide range of reformulated thermostable and fridge free StablevaX vaccines
Debasish Talukdar
President, Global Head of Advisory of Prescient Healthcare Group
Follow Debasish Talukdar:
About Prescient Healthcare Group: Prescient Healthcare Group was founded in London in 1995, originally specializing in competitive insights.
Rakesh Verma
President of Prescient Healthcare Group
Rakesh is the President of our EMEA and APAC businesses. After earning a degree in veterinary medicine, he completed his Master’s and doctoral degrees in immunology at Imperial College, School of Medicine, London. He was then recruited by oncology biotech firm Antisoma, which specialized in the development and out-licensing of monoclonal antibodies. He joined Prescient in 2007. His renowned expertise in the development and commercialization of biologics makes him an extremely valuable asset to our oncology, immunology and biosimilar clients.
Follow Rakesh Verma:
About Prescient Healthcare Group: Prescient Healthcare Group was founded in London in 1995, originally specializing in competitive insights.
Paul Marcun
Executive Vice President, Chronic Care of Coloplast Denmark
Paul Marcun is the Executive Vice President of Chronic Care at Coloplast.
Follow Paul Marcun:
About Coloplast Denmark: Coloplast is a Danish company that develops and markets products and services related to ostomy, urology, continence, and wound care.
Clive Morris
President & Chief Executive Officer of Inivata
Follow Clive Morris:
About Inivata: Inivata is a clinical cancer genomics company harnessing the emerging potential of circulating DNA analysis.
Keith Sturges
Senior Vice President International & Marketing of Sunquest Information Systems
With more than 20 years of global leadership experience in software and services companies, Keith leads Sunquest’s international business focused on extending the Sunquest brand and solutions to healthcare organizations across the world. Prior to joining Sunquest, Keith served as executive vice president of sales and implementation for Craneware, a provider of healthcare revenue cycle management tools. He has also held executive leadership positions with SirsiDynix International, Homecare Systems at Misys PLC, Allscripts Healthcare Solutions, Inc. (formerly, Allscripts-Misys Healthcare Solutions Inc., Misys Healthcare Systems LLC) and Oracle. Keith holds a Master’s of Business Administration and Computer Science from the University of Warwick in the United Kingdom.
Follow Keith Sturges:
About Sunquest Information Systems: Sunquest is the market leader in the laboratory. Sunquest Information Systems, Inc.
Bryan Olin
Senior Vice President of LivaNova
Bryan Olin, PhD is the Senior Vice President, Clinical, Quality & Regulatory Affairs at LivaNova. Dr. Olin joined Cyberonics in May 2009 as Vice President, Quality. In August 2009, he assumed additional responsibility for Clinical Affairs, and in April 2011, his responsibilities were expanded again to include Regulatory Affairs. With the 2015 merger between Cyberonics and Sorin, his responsibilities expanded to include corporate-wide responsibilities for the clinical, quality and regulatory affairs functions at LivaNova. Prior to May 2009, Dr. Olin was employed at Zeltiq Aesthetics, Inc., a privately held medical technology company in the San Francisco area, where he served as Sr. Director, Quality Assurance since October 2007. Prior to Zeltiq Aesthetics, Dr. Olin was employed at the LifeScan and Cordis companies of Johnson & Johnson from 1999 to 2007, holding several positions of increasing responsibility in quality assurance, statistics and clinical data management. Dr. Olin began his career with Procter & Gamble in 1993 after obtaining his Ph.D. in Statistics from Iowa State University. He currently serves on the board of directors for the Medical Devices Innovation Consortium (MDIC) and as an industry representative on the Advisory Committee for The National Patient-Centered Clinical Research Network (PCORnet).
Follow Bryan Olin:
About LivaNova: LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment.
Keith Ballingall
President of HealthApply
Follow Keith Ballingall:
About HealthApply: HealthApply Federal Marketplace subsidized health insurance information and enrollment assistance, concentrating on New Hampshire.
Kim Fieldbinder
Executive Vice President & Chief Financial Officer of SourceMedical-TherapySource
Kim Fieldbinder joined SourceMed as a senior accountant in August of 2001 and is currently the Company’s Executive Vice President and Chief Financial and Administrative Officer. Recently, Kim was named to the Birmingham Business Journal’s prestigious Top 40 Under 40 list for her impressive contributions to the area’s business industry and her work with SourceMed. During her time with the company, Kim has not only paved the way for female leaders as the first woman to be made a SourceMed executive, but has also helped create a leadership training and mentoring program to provide guidance and advisement to up-and-coming employees and the company’s first corporate giving program, Source Cares, which focuses on bringing hope to pediatric cancer patients. Prior to joining SourceMed, Kim was a senior accountant at Ernst & Young, LLP where she assisted in the financial audits of public companies. Kim is a certified public accountant and holds a Bachelor’s degree in accounting from the University of Alabama at Birmingham as well as a Master’s degree in accounting from the University of Alabama. Kim has been in the Birmingham market for over 18 years. She engages projects with intensity and a commitment to excellence. Kim is a team builder, facilitator, and problem- solver who propels companies forward. She resides in Birmingham with her husband and their son and spends her free time serving on the boards of many local charities.
Follow Kim Fieldbinder:
About Randall-Reilly, SourceMedical-TherapySource: SourceMedical-TherapySource provider of outpatient information solutions.
Jim Knight
President of xRapid
Follow Jim Knight:
About xRapid: xRapid is a mobile health diagnosis through disruptive solutions leveraging the use of artificial intelligence.
Kris Famm
President of Galvani Bioelectronics
Molecular biologist turned bioelectrician, Kris Famm leads Galvani Bioelectronics, a partnership between GSK and Alphabet to develop implantable medical devices.
Follow Kris Famm:
About Galvani Bioelectronics: Galvani Bioelectronics is developing ways to treat chronic illnesses by controlling electrical impulses in the body.
Stephen Langlois
Vice President of Actuarial of Coverys
Steve Langlois has been with Coverys since 1989 and manages the actuarial function for the entire organization as the vice president of actuarial. Langlois first joined the organization as an underwriting assistant and has worked as an underwriter, a statistical analyst and actuarial analyst during his tenure with Coverys. Langlois received a Bachelor of Arts degree in mathematics from Boston College and an associate degree in underwriting designation from the Insurance Institute of America.
Follow Stephen Langlois:
About Coverys: Coverys is a provider of medical professional liability insurance for physicians, hospitals, dentists and advanced practice providers.
Stephen Langlois
Vice President of Actuarial of Coverys
Steve Langlois has been with Coverys since 1989 and manages the actuarial function for the entire organization as the vice president of actuarial. Langlois first joined the organization as an underwriting assistant and has worked as an underwriter, a statistical analyst and actuarial analyst during his tenure with Coverys. Langlois received a Bachelor of Arts degree in mathematics from Boston College and an associate degree in underwriting designation from the Insurance Institute of America.
Follow Stephen Langlois:
About Coverys: Coverys is a provider of medical professional liability insurance for physicians, hospitals, dentists and advanced practice providers.
Tony Brown
Vice President of Scientific and Corporate Development of Asterand
Tony has been with Asterand Bioscience for 16 years. Prior to taking up his current position, he held a number of senior positions within the company including General Manager for the UK Services business, General Manager for the Detroit-based tissue products business and VP, Strategic Alliances, with responsibility for securing and managing the Company’s human tissue supply collaborations. Tony began his career teaching physiology at Nottingham University Medical School in the UK, after obtaining degrees in engineering, bioengineering and a PhD in physiology. He subsequently joined SmithKline Beecham in 1988, where he headed up the receptor pharmacology group within neurosciences research, and led several drug discovery projects and drug screening programs. Tony joined Pharmagene (now Asterand Bioscience) in 1998. Tony has published on the pharmacology and biochemistry of ion and neurotransmitter transport and on the use of human tissues for research in drug discovery and development.
Follow Tony Brown:
About Asterand: Asterand Bioscience is the leading global provider of high quality, well characterized human tissue & human tissue-based research solution.
Jim Beagle
President and CEO of BridgeHead Software
Jim has worked in the technology, distribution and consulting markets for more than 25 years in director-level positions. As President and CEO Jim brings his expertise of delivering business growth and profitability to BridgeHead worldwide. He previously was executive vice president of worldwide sales and services at CarbonFlow Corporation. Prior to that, he served as CEO of Extraprise International; divisional vice president of Object Design, Inc.; European director of UIS (one of the companies that formed Sprint) and a number of sales and marketing roles at ICL (now part of Fujitsu). Jim holds an MBA from Henley Management College, as well as a Diploma in Management Studies from Kingston Management College, and a degree from the London School of Economics.
Follow Jim Beagle:
About BridgeHead Software: BridgeHead Software delivers data management solutions to healthcare organizations across the globe enabling them to improve patient care.
Brad Bailey
Vice President of Sales of Ivy Sports Medicine
Brad Bailey, Vice President of Sales brings over 19 years of experience in the medical device industry with a focus in Sales management and Marketing. He has extensive experience in building teams to execute sucessful product launches and realize sustained sales growth. Mr. Bailey has worked in and run sales organizations focusing in Sports Medicine, he was Director of Sales of the Sports Tissue and Biologics Division at ConMed Corportation. He has also held leadership positions with the Musculoskeletal Transplant Foundation (MTF), DePuy Spine and Spar Medical. Mr. Bailey graduated from Birmingham Southern College in 1993 with a B.S. in Management.
Follow Brad Bailey:
About Ivy Sports Medicine: Ivy Sports Medicine is a young, dynamic company with extensive expertise in the development and production of meniscus implants.
Douglas Anderson
Founder & Vice President of Global Advocacy of Optos
Founder & Vice President of Global Advocacy, Optos plc, Douglas has a 35 year business career yielding huge experience in almost every aspect, and at every level, of healthcare technology development and commercialisation; initially as a highly creative hands-on designer, then as a design manager and technology innovator, transitioning through sales and marketing, and finally into business leadership as a serial entrepreneur.
Follow Douglas Anderson:
About Optos: Optos operates as a medical retinal imaging company.
Sofi Bergkvist
President of Center for Care Innovations
Follow Sofi Bergkvist:
About Center for Care Innovations: CCI — the Center for Care Innovations — is a vital source of ideas, best practices and funding for California’s health care safety net.
Robert Spavin
Vice President of Legal Affairs of Virttu Biologics
Robert joined VIRTTU in 2003 as Legal Counsel responsible for the company’s legal and intellectual property affairs. Qualifying as a solicitor with City of London firm Herbert Smith in 1996, he subsequently specialised in IP law at leading IP firm Bird & Bird. He is experienced in the development of growth technology companies, patent management and regulatory affairs.
Follow Robert Spavin:
About Virttu Biologics: Virttu is a privately held biotechnology company, which has pioneered the development of oncolytic viruses for treating cancer.
Alex Graham
Vice President of Translational Medicine of Virttu Biologics
Dr. Alex Graham has more than 30 years of experience as a scientist in the biotechnology and pharmaceutical sector, having most recently worked as a Principal Scientist for AstraZeneca. He has led several small molecule discovery projects and most recently was responsible for the Genomics Facility for AstraZeneca Oncology. He was also responsible for introducing relevant new technologies into the Oncology business, specifically in the areas of biomarkers and translational medicine. Alex joined Virttu in 2008 and has been closely involved in the planning,management and analysis of Virttu’s clinical studies.
Follow Alex Graham:
About Virttu Biologics: Virttu is a privately held biotechnology company, which has pioneered the development of oncolytic viruses for treating cancer.
Peter George
Chairman & President of Enigma Holding Group
Follow Peter George:
About Enigma Holding Group: Enigma is an investment company that focuses on the areas of health and wellbeing, sport, learning, community programs, and social housing.
David Freedman
COO and President of Nanoview Biosciences
Follow David Freedman:
About Nanoview Biosciences: Nanoview Biosciences is developing proprietary products that support research, translation and delivery of precision medicine.
Robin Marriott
Co-Founder and Executive Vice President of Pharmaceutical Development of PowderMed
PowderMed at Co-Founder.
Follow Robin Marriott:
About PowderMed: PowderMed developed the Particle Mediated Epidermal Delivery (PMED) technology.
Jerome Declerck
Vice President Research & Develop,ment of Optellum
Follow Jerome Declerck:
About Optellum: Optellum develops an imaging biomarker for smart lung cancer detection.
Maria Karam
Founder, President of Tactile Audio Displays Inc.
Follow Maria Karam:
About Tactile Audio Displays Inc.: R&D Leaders in Sound Systems for the body
Raymond Hill
President of Emeritus of British Pharmacological Society
Prof. Raymond Hill currently holds several board seats and professorships. He also serves as President Emeritus of the British Pharmacological Society, as a co-opted member of Council, Academy of Medical Sciences and sits on the Advisory Council on Misuse of Drugs. Dr Hill was Executive Director, Licensing and External Research, Europe for Merck, Sharp and Dohme (MSD). He additionally had oversight responsibility for Neuroscience research at the MSD / Banyu Research Labs in Tsukuba, Japan. At MSD he chaired discovery project teams responsible for currently marketed products Maxalt and Emend. Dr Hill is a non-executive director of Avilex, Covagen and Orexo. He is visiting professor at Imperial College in London, and the University of Bristol. Dr Hill received BPharm and PhD degrees from the University of London and was elected to Fellowship of the Academy of Medical Sciences in 2005.
Follow Raymond Hill:
About British Pharmacological Society, Covagen, Orexo: Formed in 1931 the BPS, including its Clinical Pharmacology Section, is the professional association for pharmacologists in the UK
Alfredo Boni
Founder & President of Creabilis
Alfredo Boni was the CEO of a large service company, Boni S.p.A, which has operated since 1964 across Europe within many industries in the field of general maintenance, cleaning and sterilization. He was also the founder of a consortium of more than 150 companies devoted to global service for various institutions including hospitals. His industrial, financial and administrative experience in founding and acquiring companies and his entrepreneurial spirit are now being devoted to the world of biotechnology.
Follow Alfredo Boni:
About Creabilis: Creabilis, a specialty pharmaceutical company focused on dermatology, discovers and develops new medicines for a range of skin disorders.
Edward K. Aldag
Chairman, President and CEO of Medical Properties Trust
Edward K. Aldag is the Chairman, President, and CEO at Medical Properties Trust.
Follow Edward K. Aldag:
About Medical Properties Trust, MPT Operating Partnership: Medical Properties Trust, Inc. bridges the gap between the growing demand for high-quality healthcare.
Nicholas Lakin
Vice President, Advisory Services of Kinapse
Follow Nicholas Lakin:
About Kinapse: Kinapse provides advisory, capability building and operational services to the life sciences industries.
